Epilepsy in Rett syndrome

Reference: 5_M.ᅠPintaudi, Abstract: Rett syndrome (SR) is a rare disease that affects about 1/10000-15000 girls. Although epilepsy is present in about 80% of these patients, clinical studies investigating the characteristics of the crisis and the use and effectiveness of anti-epileptic drugs are scarce. The study aims to: Clinical study of epilepsy in the SR, the … Read more

Training Project and collaboration with Dr. Meir Lotan * and an Italian team on rehabilitation in Rett Syndrome

Reference: 7_Dr. M. Rodocanachi – Centre Don Calabria Milan. Abstract: On days 23-24 and 25 January 2009, at the Don Calabria Institute of Milan was held a meeting with Meir Lotan, specialist physiotherapist, Ph.D. at the University of Bergen – Norway, the Department of Master of Physiotherapy ‘ University of Tel Aviv. Work in Israel, … Read more

Study of the genetic differences between the classical form and the variant to preserved language of Rett Syndrome

Reference: 1_Renieri Abstract: The preserved speech variant (Preserved Speech Variant, PSV) of Rett syndrome is characterized by a more favorable clinical course than the classical form (Zappella 1992). During the third stage, the PSV patients recover previously lost some skills: begin communicating with short sentences usually in the third person and observe an improvement in … Read more

Rett Disorder: The pre-regression period

Reference: 325 Franz-Lanyar-Stiftung Abstract: n.a PROJECT DETAILS  beginning: 2007. end: 2008. Country of research: Austria Counry of funding source: Austria Funding organization: Franz-Lanyar-Stiftung, Graz, Austria Financing: PRIVATE FUNDERS – 1 200 € hyperlink

Therapeutic approaches of Rett syndrome: development of human cell models and high-throughput screening of chemical molecules in order to identify new subtsances likely to induce readthrough of a stop codon

Reference: ANRn.a.6-MRARn.a.003 Abstract: Rett syndrome (RTT) is a neurodevelopmentale dominant X-linked disease affecting almost exclusively girls. Significant progress was the discovery of mutations in the MECP2 gene in over 90% of RTT patients. In recent years, we have developed a French consortium and determined the spectrum of mutations MECP2. We have shown that the four … Read more

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close